Periventricular leukomalacia (PVL) is the most frequent cause of cerebral palsy and other intellectual disabilities, and currently there is no treatment. In PVL, glutamate excitotoxicity (GME) leads to abnormal oligodendrocytes (OLs), myelin deficiency, and ventriculomegaly. We have previously identified that the combination of transferrin and insulin growth factors (TSC1) promotes endogenous OL regeneration and remyelination in the postnatal and adult rodent brain. Here, we produced a periventricular white matter lesion with a single intracerebral injection of N-methyl-d-aspartate (NMDA). Comparing lesions produced by NMDA alone and those produced by NMDA + TSC1 we found that: NMDA affected survival and reduced migration of OL progenitors (OLPs). In contrast, mice injected with NMDA + TSC1 proliferated twice as much indicating that TSC1 supported regeneration of the OLP population after the insult. Olig2-mRNA expression showed 52% OLP survival in mice receiving a NMDA injection and increased to 78% when TSC1 + NMDA were injected simultaneously and ventricular size was reduced by TSC1. Furthermore, in striatal slices TSC1 reduced the inward currents induced by NMDA in medium-sized spiny neurons, demonstrating neuroprotection. Thus, white matter loss after excitotoxicity can be partially rescued as TSC1 conferred neuroprotection to preexisting OLP and regeneration via OLP proliferation. Furthermore, we showed that early TSC1 administration maximizes neuroprotection.
References
[1]
Nave, K.A. Myelination and the trophic support of long axons. Nat. Rev. Neurosci. 2010, 11, 275–283, doi:10.1038/nrn2797.
[2]
Blumenthal, I. Periventricular leucomalacia: A review. Eur. J. Pediatr. 2004, 163, 435–442, doi:10.1007/s00431-004-1477-y.
[3]
Du Plessis, A.J.; Volpe, J.J. Perinatal brain injury in the preterm and term newborn. Curr. Opin. Neurol. 2002, 15, 151–157, doi:10.1097/00019052-200204000-00005.
[4]
Goldberg, M.P.; Ransom, B.R. New light on white matter. Stroke 2003, 34, 330–332, doi:10.1161/01.STR.0000054048.22626.B9.
[5]
Deng, W. Neurobiology of injury to the developing brain. Nat. Rev. Neurol. 2010, 6, 328–336, doi:10.1038/nrneurol.2010.53.
[6]
Dammann, O.; Leviton, A. Does prepregnancy bacterial vaginosis increase a mother’s risk of having a preterm infant with cerebral palsy? Dev. Med. Child Neurol. 1997, 39, 836–840, doi:10.1111/j.1469-8749.1997.tb07554.x.
[7]
Dammann, O.; Leviton, A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr. Res. 1997, 42, 1–8, doi:10.1203/00006450-199707000-00001.
[8]
Volpe, J.J. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr. Res. 2001, 50, 553–562, doi:10.1203/00006450-200111000-00003.
[9]
Brunssen, S.H.; Harry, G.J. Diffuse white matter injury and neurologic outcomes of infants born very preterm in the 1990s. J. Obstet. Gynecol. Neonatal Nur. 2007, 36, 386–395, doi:10.1111/j.1552-6909.2007.00156.x.
[10]
Back, S.A.; Rivkees, S.A. Emerging concepts in periventricular white matter injury. Semin. Perinatol. 2004, 28, 405–414, doi:10.1053/j.semperi.2004.10.010.
[11]
Hagberg, H.; Peebles, D.; Mallard, C. Models of white matter injury: Comparison of infectious, hypoxic-ischemic, and excitotoxic insults. Ment. Retard. Dev. Disabil. Res. Rev. 2002, 8, 30–38, doi:10.1002/mrdd.10007.
[12]
Mesples, B.; Plaisant, F.; Fontaine, R.H.; Gressens, P. Pathophysiology of neonatal brain lesions: Lessons from animal models of excitotoxicity. Acta Paediatr. 2005, 94, 185–190, doi:10.1080/08035250410022378.
[13]
Rees, S.; Inder, T. Fetal and neonatal origins of altered brain development. Early Hum. Dev. 2005, 81, 753–761, doi:10.1016/j.earlhumdev.2005.07.004.
[14]
Karadottir, R.; Cavelier, P.; Bergersen, J.H.; Attwell, D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005, 438, 1162–1166, doi:10.1038/nature04302.
[15]
Salter, M.G.; Fern, R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 2005, 438, 1167–1171, doi:10.1038/nature04301.
[16]
Kumar, S.; Macklin, W.B.; Gordon, M.N.; Espinosa de los Monteros, A.; Cole, R.; Scully, S.A.; de Vellis, J. Transcriptional regulation studies of myelin associated genes in md mutant rats. Dev. Neurosci. 1990, 12, 316–325, doi:10.1159/000111860.
[17]
Espinosa de los Monteros, A.; Kumar, S.; Scully, R.; Cole, R.; de Vellis, J. Transferrin gene expression and secretion by rat brain cells in vitro. J. Neurosci. Res. 1990, 25, 576–580, doi:10.1002/jnr.490250416.
[18]
Espinosa de los Monteros, A.; de Vellis, J. Myelin basic protein and transferrin characterize different subpopulations of oligodendrocytes in rat primary glial cultures. J. Neurosci. Res. 1988, 21, 181–187, doi:10.1002/jnr.490210210.
[19]
Espinosa de los Monteros, A.; Zhang, M.; Gordon, M.N.; Kumar, S.; Scully, S.; de Vellis, J. The myelin-deficient rat mutant: Partial recovery of oligodendrocyte maturation in vitro. Dev. Neurosci. 1990, 12, 326–339, doi:10.1159/000111861.
[20]
Espinosa de los Monteros, A.; Kumar, S.; Zhao, P.; Huang, J.C.; Nazarian, R.; Pan, T.; Scully, S.; Chang, R.; de Vellis, J. Transferrin is an essential factor for myelination. Neurochem. Res. 1999, 24, 235–248.
[21]
Espinosa-Jeffrey, A.; Zhao, P.M.; Awosika, O.; Huang, A.; Chang, R.; de Vellis, J. Transferrin regulates transcription of the MBP gene and its action synergizes with IGF-1 to enhance myelinogenesis in the md rat. Dev. Neurosci. 2002, 24, 227–241, doi:10.1159/000065698.
[22]
Yamaguchi, M.; Saito, H.; Suzuki, M.; Mori, K. Visualization of neurogenesis in the central nervous system using nestin promoter-GFP transgenic mice. Neuroreport 2000, 11, 1991–1996, doi:10.1097/00001756-200006260-00037.
[23]
Espinosa-Jeffrey, A.; Zhao, P.; Awosika, W.; Wu, N.; Macias, F.; Cepeda, C.; Levine, M.; de Vellis, J. Activation, proliferation and commitment of endogenous, stem/progenitor cells to the oligodendrocyte lineage by a combination of neurotrophic factors in a rat model of dysmyelination. Dev. Neurosci. 2006, 28, 488–498, doi:10.1159/000095111.
[24]
Espinosa de los Monteros, A.; Zhan, M.; Gordon, G.M.; Aymie, M.; Vellis, J. Transplantation of cultured premyelinating oligodendrocytes into normal and myelin-deficient rat brain. Dev. Neurosci. 1992, 14, 98–104, doi:10.1159/000111653.
[25]
Ma, J.; Matsumoto, M.; Tanaka, K.; Takebayashi, H.; Ikenaka, K. An animal model for late onset chronic demyelination disease caused by failed terminal differentiation of oligodendrocytes. Neuron Glia Biol. 2005, 2, 81–91, doi:10.1017/S1740925X06000056.
[26]
Espinosa-Jeffrey, A.; Hitoshi, S.; Zhao, P.; Awosika, O.; Agbo, C.; Olaniyan, E.; Garcia, J.; Valera, R.; Thomassian, A.; Chang, W.R.; et al. Functional central nervous system myelin repair in an adult mouse model of demyelination caused by proteolipid protein overexpression. J. Neurosci. Res. 2010, 88, 1682–1694.
[27]
Mallory, F.B. Pathological Technique: A Practical Manual for Workers in Pathological Histology Including Directions for the Performance of Autopsies and for Microphotography; W.B. Saunders: Philadelphia, PA, USA, 1942; p. 237.
[28]
Fleiss, B.; Gressens, P. Tertiary mechanisms of brain damage: A new hope for treatment of cerebral palsy? Lancet Neurol. 2012, 11, 556–566, doi:10.1016/S1474-4422(12)70058-3.
[29]
Espinosa de los Monteros, A.; Baba, H.; Zhao, P.M.; Pan, T.; Chang, R.; de Vellis, J.; Ikenaka, K. Remyelination of the adult demyelinated mouse brain by grafted oligodendrocyte progenitors and the effect of B-104 cografts. Neurochem. Res. 2001, 26, 673–682, doi:10.1023/A:1010943505013.
[30]
Miller, S.P.; Ferriero, D.M. From selective vulnerability to connectivity: Insights from newborn brain imaging. Trends Neurosci. 2009, 32, 496–505, doi:10.1016/j.tins.2009.05.010.
[31]
Sprinkle, T.J. 2′,3′-Cyclic nucleotide 3′-phosphodiesterase, an oligodendrocyte-Schwann cell and myelin-associated enzyme of the nervous system. Crit. Rev. Neurobiol. 1989, 4, 235–301.
[32]
Vogel, U.S.; Thompson, R.J. Molecular structure, localization, and possible functions of the myelin-associated enzyme 2′,3′-cyclic nucleotide 3′-phosphodiesterase. J. Neurochem. 1988, 50, 1667–1677, doi:10.1111/j.1471-4159.1988.tb02461.x.
[33]
Giulian, D.; Moore, S. Identification of 2′,3′-cyclic nucleotide 3′-phosphodiesterase in the vertebrate retina. J. Biol. Chem. 1980, 255, 5993–5995.
Weissbarth, S.; Maker, H.S.; Raes, I.; Brannan, T.S.; Lapin, E.P.; Lehrer, G.M. The activity of 2′,3′-cyclic nucleotide 3′-phosphodiesterase in rat tissues. J. Neurochem. 1981, 37, 677–680.
[36]
Baumann, N.; Pham-Dinh, D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol. Rev. 2001, 81, 871–927.
[37]
Bartlett, W.P.; Li, X.S.; Connor, J.R. Expresion of transferring mRNA in the CNS of normal and jimpy mice. J. Neurochem. 1991, 57, 318–322, doi:10.1111/j.1471-4159.1991.tb02130.x.
[38]
Barlett, W.P.; Li, X.S.; Williams, M.; Benkovic, S. Localization of insulin-like growth factor-1 mRNA in murine central nervous system during postnatal development. Dev. Biol. 1991, 147, 239–250, doi:10.1016/S0012-1606(05)80021-1.
[39]
Escobar, O.P.; Bongarzone, E.R.; Soto, E.F.; Pasquini, J.M. Single intracerebral injection of apo-transferrin in young rats induces increased myelination. Dev. Neurosci. 1994, 16, 248–254, doi:10.1159/000112116.
[40]
Adamo, A.M.; Paez, P.M.; Escobar-Cabrera, O.R.; Wolfson, M; Franco, P.G.; Pasquini, J.M.; Soto, E.F. Remyelination after cuprizone-induced demyelination in the rat is stimulated by apotransferrin. Exp. Neuol. 2006, 198, 519–529.
[41]
Saleh, M.C.; Espinosa de los Monteros, A.; de Arriba Zerpa, G.A.; Fontaine, I.; Piaud, O.; Djordjijevic, D.; Baroukh, N.; Garcia Otin, A.L.; Ortiz, E.; Lewis, S.; et al. Myelination and motor coordination are increased in transferrin transgenic mice. J. Neurosci. Res. 2003, 72, 587–594, doi:10.1002/jnr.10619.
[42]
Fernandez, A.M.; Torres-Alemán, I. The many faces of insulin-like peptide signalling in the brain. Nat. Rev. Neurosci. 2012, 13, 225–239, doi:10.1038/nrn3209.
[43]
McMorris, F.A.; Duboi-Dalcq, M. Insulin-like growth factor I promotes cell proliferation and oligodendroglial commitment in rat glial progenitor cells developing in vitro. J. Neurosci. Res. 1988, 21, 199–209, doi:10.1002/jnr.490210212.
[44]
McMorris, F.A.; McKinnon, R.D. Regulation of oligodendrocyte development and CNS myelinationby growth factors: Prospects for therapy of demyelinating disease. Brain Pathol. 1996, 6, 313–329, doi:10.1111/j.1750-3639.1996.tb00858.x.
[45]
Werner, H.; Woloschak, M.; Adamo, M.; Shen-Orr, Z.; Roberts, C.T., Jr.; LeRoith, D. Developmental regulation of the rat insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. USA 1989, 86, 7451–7455.
[46]
Madathil, S.K.; Evans, H.N.; Saatman, K.E. Temporal and regional changes in IGF-1/IGF-1R signaling in the mouse brain after traumatic brain injury. J. Neurotrauma 2010, 27, 95–107, doi:10.1089/neu.2009.1002.
[47]
Zapf, J.; Froesch, E.R. Insulin-like growth factor I actions on somatic growth. Compr. Physiol. 2011, 24, 663–699.
[48]
Rosenberg, P.A.; Dai, W.; Gan, X.D.; Ali, S.; Fu, J.; Back, S.A; Sanchez, R.M.; Segal, M.M.; Follett, P.L.; Jensen, F.E.; et al. Mature myelin basic protein-expressing oligodendrocytes are insensitive to kainate toxicity. J. Neurosci. Res. 2003, 71, 237–245, doi:10.1002/jnr.10472.
[49]
Marcu, M.G.; Schulte, T.W.; Neckers, L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl. Cancer Inst. 2000, 92, 242–248, doi:10.1093/jnci/92.3.242.
[50]
Xiao, X.; Zuo, X.; Davis, A.A.; McMillan, D.R.; Curry, B.B.; Richardson, J.A.; Benjamin, I.J. HSF1 is required for extra-embryonic development, postnatal growth and protection during inflammatory responses in mice. EMBO J. 1999, 18, 5943–5952, doi:10.1093/emboj/18.21.5943.
[51]
Prodromou, C.; Panaretou, B.; Chohan, S.; Siligardi, G.; O’Brien, R.; Ladbury, J.E.; Roe, S.M.; Piper, P.W.; Pearl, L.H. The ATPase cycle of Hsp90 drives a molecular ‘clamp’ via transient dimerization of the N-terminal domains. EMBO J. 2000, 19, 4383–4392, doi:10.1093/emboj/19.16.4383.
[52]
Panaretou, B.; Siligardi, G.; Meyer, P.; Maloney, A.; Sullivan, J.K.; Singh, S.; Millson, S.H.; Clarke, P.A.; Naaby-Hansen, S.; Stein, R.; et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol. Cell 2002, 10, 1307–1318, doi:10.1016/S1097-2765(02)00785-2.
[53]
Spence, R.D.; Hamby, M.E.; Umeda, E.; Itoh, N.; Du, J.; Wisdom, S.; Cao, Y.; Bondar, G.; Lam, J.; Ao, Y.; et al. Neuroprotection mediated through estrogen receptor-alpha in astrocytes. Proc. Natl. Acad. Sci. USA 2011, 108, 8867–8872, doi:10.1073/pnas.1103833108.
[54]
Passinen, S.; Valkila, J.; Manninen, T.; Syvala, H.; Ylikomi, T. The C-terminal half of Hsp90 is responsible for its cytoplasmic localization. Eur. J. Biochem. 2001, 268, 5337–5342, doi:10.1046/j.0014-2956.2001.02467.x.
[55]
Picard, D.; Yamamoto, K.R. Two signals mediate hormone-dependent nuclear localization of the glucocorticoid receptor. EMBO J. 1987, 6, 3333–3340.
[56]
Dickey, C.A.; Eriksen, J.; Kamal, A.; Burrows, F.; Kasibhatla, S.; Eckman, C.B.; Hutton, M.; Petrucelli, L. Development of a high throughput drug screening assay for the detection of changes in tau levels—Proof of concept with HSP90 inhibitors. Curr. Alzheimer Res. 2005, 2, 231–238, doi:10.2174/1567205053585927.
[57]
Fujikake, N.; Nagai, H.; Popiel, H.A.; Okamoto, Y.; Yamaguchi, M.; Toda, T. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J. Biol. Chem. 2008, 283, 26188–26197, doi:10.1074/jbc.M710521200.
[58]
Auluck, P.K.; Meulener, M.C.; Bonini, N.M. Mechanisms of suppression of α-synuclein neurotoxicity by geldanamycin in drosophilia. J. Biol. Chem. 2005, 280, 2873–2878.
[59]
Waza, M.; Adachi, H.; Katsuno, M.; Minamiyama, M.; Tanaka, F; Sobue, G. Alleviating neurodegeneration by an anticancer agent: An Hsp90 inhibitor (17-AAG). Ann. N. Y. Acad. Sci. 2006, 1086, 21–34, doi:10.1196/annals.1377.012.
Taldone, T.; Gozman, A.; Maharaj, R.; Chiosis, G. Targeting Hsp90: Small-molecule inhibitors and their clinical development. Curr. Opin. Pharmacol. 2008, 8, 370–374, doi:10.1016/j.coph.2008.06.015.
[62]
Heath, E.L.; Gaskins, M.; Pitot, H.C.; Pili, R.; Tan, W.; Marschke, R.; Liu, G.; Hillman, D.; Sarkar, F.; Sheng, S.; et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Prostate Cancer 2005, 4, 138–141, doi:10.3816/CGC.2005.n.024.
[63]
Ramanathan, R.K.; Trump, D.L.; Eiseman, J.L.; Belani, C.P.; Agarwala, S.S.; Zuhowski, E.G.; Lan, J.; Potter, D.M.; Ivy, S.P.; Ramalingam, S.; et al. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin. Cancer Res. 2005, 11, 3385–3391, doi:10.1158/1078-0432.CCR-04-2322.
[64]
DiFiglia, M. Excitotoxic injury of the neostriatum: A model for Huntington’s disease. Trends Neurosci. 1990, 7, 286–289, doi:10.1016/0166-2236(90)90111-M.
